Prolia (denosumab) is a monoclonal antibody. Monoclonal antibodies are made to target and destroy only certain cells in the body. This may help to protect healthy cells from damage.
The Prolia brand of denosumab is used to treat osteoporosis in postmenopausal women who have high risk of bone fracture.
Prolia is used to increase bone mass in men with osteoporosis with a high risk of bone fracture, and in women and men with a high risk of bone fracture caused by receiving treatments for certain types of cancer.
Prolia is also used to treat glucocorticoid-induced osteoporosis in men and women at high risk of bone fracture.